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ABSTRACT
Objectives: Comprehensive Geriatric Assessment (CGA), the gold standard for 
detecting frailty in elderly cancer patients, is time-consuming and hard to apply in 
routine clinical practice. Here we compared the performance of two screening tools 
for frailty, G8 and SAOP2 for their accuracy in identifying vulnerable patients.
Material and Methods: We tested G8 and SAOP2 in 282 patients aged 65 or older 
with a diagnosis of solid cancer and candidate to undergo surgical, medical and/or 
radiotherapy treatment. CGA, including functional and cognitive status, depression, 
nutrition, comorbidity, social status and quality of life was used as reference. ROC 
curves were used to compare two screening tools.
Results: Mean patient age was 79 years and 54% were female. Colorectal and 
breast cancer were the most common types cancer (49% and 24%). Impaired CGA, 
G8, and SAOP2 were found in 62%, 89%, and 94% of the patients, respectively. 
SAOP2 had a better sensitivity (AUC 0.85, p<0.032) than G8 (AUC 0.79), with higher 
performance in breast cancer patients (AUC 0.93) and in patients aged 70-80 years 
(AUC 0.87).
Conclusions: G8 and SAOP2 both showed good screening capacity for frailty in 
the cancer patient population we examined with SAOP2 showing a slightly better 
performance than G8.
INTRODUCTION
The risk of cancer increases with age [1]. Already 
as of today, more than half of the patients who are 
newly diagnosed with cancer are older than 65 and this 
percentage is projected to increase to 70% by 2030 [2, 
3]. This “oncogeriatric” population will benefit from 
the development of innovative therapies or surgical 
procedures, which will, however, require specific clinical 
management [4].
Despite the increasing rate of elderly cancer patients, 
there is a major gap of knowledge on how to properly 
stratify older patients according to their biological status, 
to be able to recommend the most appropriate type of 
treatment in a personalized fashion.
The Comprehensive Geriatric Assessment (CGA) is 
a multidimensional, interdisciplinary evaluation that leads 
to the identification and stratification of patients’ clinical 
vulnerability.
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According to the International Society of Geriatric 
Oncology (SIOG), the CGA remains the gold standard for 
defining the presence and or the degree of frailty in elderly 
cancer patients; its widespread use is recommended, 
particularly since the CGA was shown to improve patient 
overall survival, functional status, and quality of life [5, 6]. 
In geriatric oncology frailty’s evaluation is mainly focused 
on person’s ability to tolerate cancer treatment; frailty is 
also associated with a worse quality of life.
However, the CGA is time and resource-consuming 
and requires the expertise of geriatricians who are not 
always available in standard cancer clinics. It remains 
poorly incorporated in routine clinical practice. Thus, 
consensus guidelines from the National Comprehensive 
Cancer Network (NCCN) [7], the European Organization 
for Research and Treatment of Cancer (EORTC) [8], 
and the SIOG [9], consider a “two-step approach” as 
a reasonable strategy, where the first step involves a 
geriatric screening test to identify patients who are at high 
risk of being frail and the second step foresees a complete 
CGA to be performed by geriatricians [1, 10–13].
Since the 2005 SIOG guidelines, a total of 17 
different tools have been studied in 44 different trials to 
evaluate the best screening test in oncogeriatrics [9]. These 
include G8, Oncogeriatric screen (OGS), Abbreviated 
Comprehensive Geriatric Assessment (aCGA), Senior 
Adult Oncology Program (SAOP) 2, Gerhematolim, 
the Vulnerable Elders Survey-13 (VES-13) and Flemish 
version of the Triage Risk Screening Tool (fTRST) [9].
So far, although the G8, the VES-13 and fTRST 
tools have shown the best clinometric properties in elderly 
patients [9], there remains a substantial uncertainty as to 
which test most adequately identifies frailty in at risk older 
cancer populations [14].
The purpose of this study was to define the accuracy 
with which two geriatric screening tools, G8 and SAOP2 
identify frail oncogeriatric patients, who are ultimately 
candidates to receive a CGA.
RESULTS
Patients’ clinical characteristics
Three hundred three eligible cancer patients were 
evaluated at the Ospedale Policlinico San Martino in 
Genoa, Italy, between January 2015 and May 2017. For 
two patients, clinical data collection was not completed 
and therefore they were not included in the study. Nineteen 
patients did not meet the inclusion criteria. Thus, 282 
eligible patients were evaluated in the study (Figure 1). 
Mean patient’s age was 79.02 years ± 5.87 (range, 65-
93 years) and about 40% of the patients were >80 years 
Figure 1: Study sample design.
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old. 54% of the patients were female and 46% were male. 
Colorectal cancer and breast cancer were the most common 
types of neoplasms for which patients were being treated, 
accounting for 50% and 24% of the patients, respectively.
Patients’ clinical characteristics, screening tools and 
CGA assessment are illustrated in Table 1 and 2.
Overall, 175 out of 282 patients (62%) showed 
problems in at least 3 CGA clinical domains, thus 
resulting as frail. This clinical vulnerability was mainly 
characterized by multimorbidity, initial functional decline 
and malnutrition risk (Table 2). In addition, patients 
reported a poor perception of the quality of life according 
to Short Form 36 (SF-36).
Notably, based on the CGA assessment, a G8 
impairment mostly reflected an increased malnutrition 
risk (Mini Nutritional Assessment-MNA) (U 642, p<0.05) 
(Table 3).
Frail patients (based on CGA assessment) scored 
positive according to G8 in 89% and to SAOP2 in 94% of 
the cases, respectively (Table 4).
The comparison between G8 and SAOP2 diagnostic 
accuracy showed that SAOP2 had fair specificity, lower 
than G8.
A pairwise comparison between SAOP2 (n=282; 
AUC 0.85; 95% CI: 0.0215-0.81130) and G8 (n=282; 
AUC 0.79; 95% CI: 0.0260-0.74478) with reference to 
CGA using ROC curves showed a higher accuracy in 
differentiating patients with abnormal CGA for the SAOP2 
screening tool (p<0.032) (Figure 2).
The diagnostic accuracy of both screening tools 
(with reference to CGA) was further assessed, separately, 
in patients with a diagnosis of breast cancer (n=68) versus 
patients with a diagnosis of colorectal cancer (n=138).
Table 1: Patients’ demographic and clinical characteristics
VARIABLE N
DEMOGRAPHICS
GENDER:
FEMALE 152
MALE 130
MEAN AGE 79.02 ± 5.87 (range 65–93 YEARS)
AGE
< 69 14
70 - 80 156
81 - 89 101
> 90 11
CANCER TYPE
COLORECTAL 138
GASTRIC AND OESOPHAGEAL 15
PANCREAS AND BILIAR TRACT 4
HEAD AND NECK 12
BREAST 68
PROSTATE 11
GYNAECOLOGICAL 11
RENAL AND BLADDER 11
LUNG 3
OTHERS 9
DISEASE STAGE
NON-METASTATIC DISEASE 186
METASTATIC DISEASE 14
UNCLASSIFIED 82
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The SAOP2 showed higher accuracy in predicting 
patients’ clinical vulnerability in breast cancer patients (n= 
68; AUC 0.93; 95% CI: 0.87822-0.98518) as compared 
to the G8 (n=68; AUC 0.79; CI: 0.68674-0.89719) 
(p<0.014). Conversely, a comparison between SAOP2 
and G8 in colorectal cancer patients did not show any 
difference in the ability to detect frail patients (p<0.160) 
(Figure 3).
In addition, in patients aged between 70 and 80 
years, SAOP2’s diagnostic accuracy (n=156; AUC 0.87; 
95% CI 0.82061-0.92710) was higher as compared to G8’s 
accuracy (n=156; AUC 0.77; 95%CI 0.70043-0.84865) 
(p<0.015).
Notably, both screening tools failed to accurately 
detect frailty in patients aged >80, with a high rate of false 
positive results (p<0.40) (Figure 4).
DISCUSSION
The integration of CGA in clinical practice could 
help oncologists tailor clinical decisions based on 
the elderly patient’s actual fitness. Currently, a two-
step approach is recommended. Nevertheless, the best 
screening tool to be applied in the clinic remains to be 
defined [14].
To the best of our knowledge, this is the first study 
to directly compare the performance of two commonly 
Table 2: G8, SAOP2 screening tools, CGA assessment with frequency of elders who were categorized as impaired in 
each domains of CGA
SCREENING TOOLS AND
CGA ASSESSMENT
CLINICAL DOMAIN CUT-OFF * IMPAIRED% MEAN SCORE ± SD
G8 ≤14 74 12.23 ± 2.75
SAOP2 >2 78 2.73 ± 1.32
MMSE COGNITIVE STATUS <24 20 26.65 ± 3.88
CDT (SCHULMAN) COGNITIVE STATUS ≥ 3 48 2.54 ± 1.40
MNA NUTRITIONAL STATUS < 23 44 22.62 ± 3.91
IADL FUNCTIONAL STATUS ≤ 7 39 6.83 ± 2.02
BARTHEL INDEX FUNCTIONAL STATUS < 50 3,5 95.98 ± 11.64
CIRS
COMORBIDITY
SEVERITY
COMORBIDITY >3 63 4.23 ± 1.831.96 ± 0.38
N° OF DRUGS - ≥ 3 57 4.48 ± 2.75
GDS PSYCHOLOGICAL STATUS ≥ 5 30 3.92 ± 3.34
TINETTI SCALE POSTURAL STABILITY ≤ 18 16,5 24.02 ± 5.74
MORSE SCALE RISK OF FALL ≥ 25 29 23.44 ± 19.94
GIJON SCALE SOCIAL STATUS ≥ 10 35 8.77 ± 2.29
SF-36 QoL 0.68 ± 0.21
CUT OFF CGA** ≥ 3 62 3.77 ± 2.56
Abbreviations: SAOP2: Senior Adult Oncology Program (SAOP) 2; MMSE: Mini Mental State Examination; CDT: Clock 
Drawing Test; MNA: Mini Nutritional Assessment ; I-ADL: Instrumental Activities of Daily Living; CIRS: Cumulative 
Illness Rating Scale; GDS: Geriatric Depression Scale; SF-36: Short Form 36; QoL: Quality of life; CGA: Comprehensive 
Geriatric Assessment.
* Cut-off score.
** cumulative number of impaired CGA domains.
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applied frailty screening tools, G8 and SAOP2, in an older 
cancer population.
Clearly, a high sensitivity and specificity are both 
desired properties of an oncogeriatric-screening tool, to 
limit the number of fit patients who unnecessarily undergo 
CGA assessment. These clinometric properties also ensure 
that frailty is properly recognized, thus avoiding that 
vulnerable subjects are over treated and exposed to the 
risk of treatment toxicity [9].
Our data show that the SAOP2 has higher diagnostic 
accuracy as compared to the G8, especially in oncogeriatric 
patients who are <80 years. Conversely, both SAOP2 and 
G8 showed adequate sensitivity at the expense of specificity 
in patients older than 80 years. Furthermore, our results 
indicate that the SAOP2 screening tool has better screening 
performance than the G8 in breast cancer patients, but not 
in patients diagnosed with colorectal cancer.
Evidence is accumulating on the role of G8 
screening tool in detecting vulnerable patients, even if 
with heterogeneous results [9, 15]. The ONCODAGE 
multicentre study [16] has validated the G8 for the 
identification of older cancer patients eligible for CGA 
assessment: sensitivity varied according to tumour site 
and stage (head and neck cancer 94%; colon cancer 88%; 
metastatic stages 87%). Further, Kenis et al [13] has 
shown high sensitivity and moderate negative predictive 
value of the G8 tool in elders with metastatic breast and 
colorectal cancer.
Conversely, the comparison among fTRST, G8, and 
Groningen Frailty Index in elderly cancer patients [17] 
has resulted in the higher diagnostic accuracy of fTRST 
(sensitivity 92%) compared to G8 (sensitivity 80%). Baitar 
et al [18] has confirmed the higher accuracy of G8 tool 
in identifying vulnerable cancer patients with prevalent 
malnutrition.
Furthermore, in neck and head cancer patients, the 
G8 tool has shown better sensitivity, compared to VES-13 
[19], and, similarly, Liu et al [20] has reported G8 higher 
Table 3: Comparison of CGA domains in patients aged between 70 and 80 years with impaired G8 and SAOP2, 
respectively
CLINICAL DOMAIN
AND TOOL
MEAN SCORE (±SD)
N 156 G8 ≤ 14
N 114
SAOP ≥ 2
N 131 P value 
b
COGNITIVE STATUS
MMSE
27.29±2.95 26.93±3.25 26.85±3.16 ns
FUNCTIONAL STATUS
BARTHEL
97.01±9.48 95.75±11.47 96.03±10.75 ns
FUNCTIONAL STATUS
IADL
7.16±1.67 6.83±1.95 6.91±1.86 ns
PHYSICAL PERFORMANCE
TUG
10.15±4.27 10.80±4.87 10.77±4.60 ns
NUTRITIONAL STATUS
MNA
22.53±4.91 20.85±4.76 21.76±4.88 U 642, p<0.05
PSYCHOLOGICAL STATUS
GDS
3.89±3.44 4.45±3.70 4.54±3.62 ns
SOCIAL STATUS
GIJON SCALE
8.53±2.36 8.99±2.44 9.02±2.39 ns
COMORBIDITY
CIRS CI
4.05±1.83 4.43±1.91 4.40±1.85 ns
QOL
SF-36
0.69±0.21 0.65±0.22 0.65±0.22 ns
b non-parametric Mann–Whitney U test.
Abbreviations: CGA: Comprehensive Geriatric Assessment; SAOP2: Senior Adult Oncology Program (SAOP) 2; MMSE: 
Mini Mental State Examination; I-ADL: Instrumental Activities of Daily Living; TUG: Timed “Up & Go” test; MNA: Mini 
Nutritional Assessment; GDS: Geriatric Depression Scale; CIRS: Cumulative Illness Rating Scale; CI: Co-morbidity Index; 
QoL: Quality of life; SF-36: Short Form 36.
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Table 4: Comparison between G8 and SAOP2 diagnostic accuracy with reference to the gold standard CGA
Sensitivity Specificity PPV NPV
G8 89% 49.5% 73.9% 73.6%
SAOP2 94% 46.9% 74% 81%
Abbreviations: CGA: Comprehensive Geriatric Assessment; SAOP2: Senior Adult Oncology Program (SAOP) 2; PPV: 
positive predictive value; NPV: negative predictive value.
Figure 3: ROC curve comparison of G8 and SAOP2 screening tools in patients with breast cancer and colon rectal 
cancer respectively. Abbreviations: ROC: Receiver operating characteristic; SAOP2: Senior Adult Oncology Program (SAOP) 2.
Figure 2: ROC curve diagnostic accuracy comparison between G8 and SAOP2 screening tools with reference to 
CGA. Abbreviations: ROC: Receiver operating characteristic; SAOP2: Senior Adult Oncology Program (SAOP) 2; CGA: Comprehensive 
Geriatric Assessment.
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sensitivity in patients with local colorectal cancer, upper 
digestive, hepatic tumour and in the metastatic group. In 
keeping with that, Pottel et al [21] has underpinned more 
impaired G8 scores in patients with advanced cancer, 
compared to early stage cancer patients.
Thus, it is plausible that subjects with more 
advanced cancer, and particularly with gastrointestinal 
and head/neck tumour are frequently comorbid for 
malnutrition [22], due to the intense inflammatory 
response associated with anorexia and cachexia [23], 
which can lead to progressive loss of skeletal muscle mass 
and worsen impairment of function [24]. Malnutrition 
has been associated with reduced ability to tolerate anti-
cancer therapy, increased severe dose-limiting toxicities, 
lesser response rates, worse quality of life, decline in 
performance status, and shorter survival outcomes [25]. 
Thus, malnutrition turns to play a key relevant weight in 
informing G8 impairment.
Indeed, G8 screening tool incorporates most of 
the MNA items and the fact that MNA was not designed 
to specifically detect an abnormal CGA may probably 
explain the lack of specificity of the G8 as a screening 
instrument [15].
Conversely, in haematological malignancies, the G8 
tool didn’t adequately discriminate unfit subjects eligible 
for CGA [26], showing moderate diagnostic accuracy. 
Hamaker et al [27] has indicated lower sensitivity but 
better specificity (respectively 69% and 79%) of G8 
screening performance due to potential higher prevalence 
of underdiagnosed geriatric syndromes.
This scientific background may count for the higher 
accuracy of SAOP2 screening in intercepting vulnerability 
in breast cancer patients compared to colorectal patients, 
as observed in the present study.
Thus, different cancer types and stages may have 
a different weighed impact on screening performance 
and overall diagnostic accuracy and the use of several 
validated CGA instruments and cut-off values may also 
add methodological biases, affecting results reliability.
Fewer evidence has shown the diagnostic accuracy 
of SAOP2 screening tool in different cancer population 
and clinical settings. However, SAOP2 tool [28] has 
shown adequate clinometric properties with reference to 
the standard geriatric assessment (sensitivity of 100% and 
a specificity of 40%) [29], including the assessment of key 
relevant issues for cancer related outcomes, such as social 
vulnerability, depression, quality of life and perceived 
health status.
Lower perceived social support is generally 
associated with higher depressive symptoms and lower 
quality of life [30, 31], especially in cancer patients 
compared to the general population [30, 32]. Thus, 
social vulnerability represents a key factor for patient’s 
compliance and the effectiveness of chemotherapy 
regimens [33, 34]. It has also been shown that social 
vulnerability and frailty are related but distinct clinical 
constructs [35] and that the former was a significant 
predictor of mortality and disability, regardless of patients’ 
frailty [36, 37].
Originally, the present findings indicate SAOP2 
better performance in patients aged 70-80 years and 
Figure 4: ROC curve comparison of G8 and SAOP2 screening tools in patients aged 70- 80 years and in patients > 80 
years. Abbreviations: ROC: Receiver operating characteristic; SAOP2: Senior Adult Oncology Program (SAOP) 2.
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support the diagnostic inaccuracy of oncogeriatric 
screenings (higher false positive screening results) in 
over octogenarian patients. The biological aging involves 
a loss of homeostasis with enhanced vulnerability 
to environmental stressors (surgical interventions or 
chemotherapy) [33, 38] that may exceed patients’ 
threshold homeostenosis, precipitating a frailty trajectory 
[39]. Moreover, it is likely that the highly individualized 
trajectory of frailty could affect the discriminative power 
of these screening tools, especially in the oldest old (>85 
years) populations [40, 41]. In turn, the time-saving 
potential of screening may outweigh the risk of incorrectly 
identifying patients, delivering inappropriate care [41].
On the basis of our results, G8 performance seems 
to be outweighed by malnutrition risk in cancer patients 
between 70 and 80 years. Conversely, SAOP2 tool did not 
show any correlation with GCA domains.
Few studies have addressed the association 
between single geriatric domains, with reference to CGA 
assessment, and oncogeriatric screening performance [41]. 
Namely, Hamaker et al. has shown that G8 had strong 
predictive ability for malnutrition, but lower predictive 
value for geriatric conditions. In addition, VES-13 had a fair 
predictive value for cognitive disorders, impaired mobility, 
and malnutrition [41]. The association of screening tools 
with social support, showed a very low diagnostic accuracy 
(VES-13 sensitivity 33%; specificity 46%) [41–44].
In our population, SAOP2 was not statistically 
associated with social domains even an association 
trend with poorer perceived health status and lack of 
support was observed. This may be due to the partial 
diagnostic accuracy of the used Gijon Scale; in turn, the 
social vulnerability index (SVI) [36], may be the most 
appropriate tool in elderly cancer patients. However, the 
lack of any Italian validation hampers the feasibility of 
such a tool in intercepting patients’ social vulnerability.
Even preliminary in nature, SAOP2 tool seems to 
better predict clinical vulnerability, especially at the earlier 
stages of cancer. This is particularly true in ‘’younger’’ 
patients with two wide prevalent cancer types.
The present study has some limitations. First, non-
metastatic colorectal and breast cancer were strongly 
represented while patients with progression/relapse of the 
disease were systematically excluded. Thus, stratification 
of patients with different cancer types and stages is still 
needed. Moreover, the single centre population may 
represent a potential bias selection.
Notwithstanding that, the strength of the study 
lies on the real-world assessment of an oncogeriatric 
population, with the direct comparison of G8 and SAOP2 
screening accuracy. Assessing this aspect would warrant 
more sophisticated study designs, including the feedback 
of a GA team, the appropriateness of the referral and the 
time frame of clinical interventions. In line with that, 
Table 5: CGA assessment, clinical domain and cut-offs
Tool CLINICAL DOMAIN NUMBER OF ITEMS RANGE CUT-OFF *
IADL FUNCTIONAL STATUS 8 0-8 ≤ 7
BARTHEL FUNCTIONAL STATUS 10 0-100 < 50
MORSE SCALE RISK OF FALL 6 0-125 ≥ 25
TINETTI SCALE POSTURAL STABILITY 16 0-28 ≤ 18
CIRS
SEVERITY
COMORBIDITY
COMORBIDITY 19
0-37
0-5
0-13
>3
MMSE COGNITIVE STATUS 7 0-30 <24
CDT COGNITIVE STATUS 1 1 -6 ≥ 3
GDS PSYCHOLOGICAL STATUS 15 0-15 ≥ 5
MNA NUTRITIONAL STATUS 18 0-30 < 23
NRS PAIN 1 0-10 ≥ 3
GIJON SCALE SOCIAL STATUS 5 5-25 ≥ 10
CGA - - - ≥ 3
Abbreviations: I-ADL: Instrumental Activities of Daily Living; CIRS: Cumulative Illness Rating Scale; SI: Illness Severity 
Index; CI: Co-morbidity Index; MMSE: Mini Mental State Examination; CDT: Clock Drawing Test Shulman; GDS: 
Geriatric Depression Scale; MNA: Mini Nutritional Assessment; NRS: Numeric Rating Scale; CGA: Comprehensive 
Geriatric Assessment.
* Cut-off score.
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the prospective nature of the present study will help the 
understating of outcome measures in terms of service 
utilization, geriatric referrals, complications, functional 
independence and survival variables.
Comparing sensitivity and specificity to CGA has 
the advantage of feasibility in a study. However, it only 
indirectly addresses the question of how useful the tool 
is for selecting patients. Therefore, which screening tool 
could best suit the older cancer populations is a matter of 
debate. The inclusion of frailty indicators and biological 
markers may add knowledge to this intriguing field and is 
part of the observational study.
Eventually, further research is needed to optimize 
the use of SAOP2 screening tool. On the basis of its 
multidisciplinary nature and the inclusion of key relevant 
issues like social vulnerability, health perceived status and 
quality of life, it has great potential of defining clinical 
pathways, targeting the quality of life and the quality of 
care in this outgrowing number of cancer patients [15].
MATERIALS AND METHODS
Study design and population
This prospective study was performed at the 
Ospedale Policlinico San Martino, Genoa, Italy, from 
January 2015 to May 2017.
Inclusion criteria were all patients over 65 years with 
a first diagnosis of solid tumour, who qualified for surgery 
and/or chemotherapy, adequate understanding of the Italian 
language and ability to sign an informed consent.
Exclusion criteria were: palliative care patients; 
severe dementia or pre-existing major neurological and/
or psychiatric disorders.
The study was approved by the ethical committee 
of the participating hospital, and written informed consent 
was obtained by all subjects or their next to kin.
Patients were simultaneously tested for G8 and 
SAOP2 questionnaire and comprehensive geriatric 
assessment, before oncological treatment (surgery, 
neoadjuvant or adjuvant chemotherapy), by an expert 
geriatrician.
First visit also included the Short Form 36 [45, 46] 
to assess quality of life.
Demographic data (age, gender), tumour 
characteristics (site, local or metastatic), proposed 
chemotherapy and/or surgery, geriatric recommended 
clinical interventions were also collected.
Test methods
G8 screening tool
The G8 screening tool was developed to identify 
elderly unfit cancer patients, eligible for geriatric assessment.
The G8 test consists of the following eight items: 
chronological age (<80, 80–85, >85 years) and seven 
clinical items including the Mini Nutritional Assessment, 
a questionnaire dealing with food intake, weight loss, 
mobility, neuropsychological comorbidity, body mass 
index, prescription drug, and self-perception of health 
status [1, 22, 40].
The total score can range from 0 to 17. A score 
of ≤14 is considered abnormal, indicating a clinical 
vulnerability profile. (Supplementary Appendix 1)
The G8 was compared in terms of clinometric 
properties with CGA in eight different studies, that 
cumulatively included 3816 patients [13, 16–20, 40, 47]. 
Sensitivity ranged from 65% to 92%, specificity ranged 
from 3% to 75% and negative predictive value (NPV) 
from 8% to 78% [9].
Senior adult oncology program (SAOP) 2
The SAOP2 screening tool was developed by the 
multidisciplinary clinical team of the SAOP at Moffitt 
Cancer Centre [10]. In addition to functional status, 
depression, and cognitive screening, the tool includes 
the assessment of health-related quality of life, self-rated 
health, falls, nutrition, sleep, multiple medications, and 
social issues (drug payment and reimbursement and 
caregiver availability) (Supplementary File 2) [10].
If 1 item is impaired, the respective specialist 
is called in, with potential secondary referral to other 
team members. If several items are impaired, the 
multidisciplinary team is called along with the geriatric 
referral for CGA assessment. SAOP2 is a sensitive tool, 
with low internal specificity, addressing the importance of 
a multidisciplinary team approach [28, 29, 48].
Comprehensive geriatric assessment (CGA)
An expert geriatrician administered the CGA 
assessment in an average time of 50 minutes. It 
evaluates the following tools to assess several clinical 
domains (Table 5): cognitive status (Mini Mental State 
Examination, MMSE [49] and Clock Drawing Test, CDT 
[50]), psychological status (Geriatric Depression scale, 
GDS 15 items [51]), functional status (Instrumental 
Activities of Daily Living, IADL, of Lawton [52] 
and Barthel Index [53]), postural stability (Tinetti 
Scale [54]), risk of falls (Morse Scale [55]), physical 
performance (Timed “Up & Go” test, TUG [56, 57]), 
nutritional status (Mini Nutritional Assessment [58]), 
social vulnerability (Gijon Scale [59]), physical burden 
of illness (Cumulative Illness Rating Scale, CIRS: 
Illness Severity Index-SI, and Co-morbidity Index-CI 
[60, 61]). Patients were categorized as impaired if the 
CGA ≥3 deficits [62].
Pain was assessed using the Numeric Rating Scale 
(NRS) [63, 64]. Polypharmacy was also collected.
Oncotarget35065www.oncotarget.com
Outcome
The primary outcome was to assess the diagnostic 
accuracy of SAOP2 and G8 screening tool, with reference 
to CGA, in detecting patient’s clinical vulnerability.
Statistical analysis
The descriptive analysis for quantitative variables 
was expressed as mean and standard deviation (SD) or 
median and interquartile range (IQR).
Sensitivity and specificity of both screening tools 
were calculated using the pre-specified cut-offs from 
literature.
Further receiver operating characteristic (ROC) 
curves were used to compare G8 and SAOP2 screening 
tools.
If present, indeterminate results were considered 
as false-positive or false-negative and incorporated into 
the final analysis. For example, an indeterminate result 
in a patient found to be frailty according to CGA was 
considered to have had a negative test result.
Area under the curves (AUC) with 95% CI were 
reported. AUCs were compared using chi-square test.
A non-parametric Mann–Whitney test was used to 
compare two variable.
A p-value <0.05 was considered statistically 
significant.
Stata (v.14; function “roccomp”; StataCorp) was 
used for the computation.
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range; AUC:Area under the curves; ROC:Receiver 
operating characteristic.
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